anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Endometrial cancer is the most common malignant tumor of the uterus, but the underlying genetic mechanisms of EC remain unclear. To identify candidate genes and investigate genetic mechanisms for endometrial cancer, we utilized the summary-data-based Mendelian randomization (SMR) method to investigate causal associations between genetic variants, gene expression, DNA methylation, and endometrial cancer. Three main analyses were conducted utilizing cis-expression and methylation quantitative trait loci (eQTLs and mQTLs) as instrumental variables to examine causal relationships with endometrial cancer, and assessing the causal relationship between DNA methylation and gene expression. Data sources included genetic association data from O'Mara et al. eQTL data from the GTEx database, and mQTL data from McRae et al. Analysis involved the HEIDI test to distinguish pleiotropy, SMR analysis with multiple testing correction, and colocalization analysis to assess associations driven by linkage disequilibrium. Functional enrichment analysis was performed by the Metascape tool. Our study showed that three genes, SNX11, LINC00243, and EVI2A, were identified as causally related to endometrial cancer. SNX11 exhibited a positive causal relationship, while LINC00243 and EVI2A showed negative ones. Furthermore, 24 CpG sites were identified as causally related to endometrial cancer, with cg14424631 (CYP19A1) being the most significant. The study revealed common genes implicated in endometrial cancer, gene expression, and methylation sites, with LINC00243 playing a key role. Colocalization analysis confirmed significant causal relationships between LINC00243, SNX11, and endometrial cancer. Enrichment analysis uncovered pathways like interferon gamma signaling enriched in both endometrial cancer GWAS and e/mQTL. These findings shed light on the molecular mechanisms underlying endometrial cancer development. The study identified candidate genes and DNA methylation loci causally associated with endometrial cancer, which are expected to serve as potential targets for treatment.
Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
The invention provides an infantile diarrhea treatment traditional Chinese medicine powder of a palm patch for external use. The traditional Chinese medicine powder comprises, by weight, 3-10 parts of tetradium ruticarpum, 3-10 parts of cinnamon, 3-10 parts of jasmine and 3-10 parts of almond. A using method includes taking 3-5 parts of the traditional Chinese medicine powder, mixing the traditional Chinese medicine powder with egg white uniformly to obtain a mixture, spreading the mixture on gauze, addressing the gauze on the Laogong acupoint of the palm of a child, and then fixing the gauze with adhesive tapes. The traditional Chinese medicine powder is prepared by natural traditional Chinese herbs completely, penetrates through skin and acupoints to act on channels of the human body, permeates the human body to mix with body fluid, dredges and stimulates the channels so as regulate the middle burner, balance and improve restoration of stomach functions. Difficulty and suffering for children due to oral medicine or infusion are avoided, a simple and easy treatment method is provided, no pain can be caused during treatment, and thus, the children can accept the treatment method easily. In addition, according to practice, 206 of 226 infantile diarrhea cases treated with the traditional Chinese medicine powder are effective and the rest 20 are noneffective, and thus the inefficiency is 8.85% while the total effective rate is 91.15%.
PURPOSE: An anti-acne cosmetic composition containing fruit juice or a extract of Benincasa hispida(Thunb.) Cogn. as a main component is provided. Also, provided is a method for production thereof. The fruit juice or extract of Benincasa hispida exhibits strong growth inhibiting activity against Propionibacterium acnes and a cosmetic composition containing the same is therefore effective for the prevention and treatment of acne. CONSTITUTION: An anti-acne cosmetic composition contains 0.001 to 20% by weight of a Benincasa hispida extract, based on the total weight of the composition. The Benincasa hispida extract is obtained by heating 1 to 20 times with an extraction solvent at 50 to 95deg.C or soaking for 1 to 15 days. The extraction solvent is one or more solvents selected from the group consisting of water, ethanol, ethyl acetate, hexane, glycerin, ethylene glycol, butylene glycol, propylene glycol, hydrous ethanol, hydrous glycerin, hydrous ethylene glycol, hydrous butylene glycol and hydrous propylene glycol.
An extract from camomile blossom with bacteriostatic and trichomonoacidal properties is obtd. by extraction of camomile tongue blossom with a small amt. (up to max. 0.3 pts.wt.) of camomile tube blossom.      The extract is pref. a pale yellow aq. soln. of pH 3-4, specific gravity 1.0004-1.0006 and contains the polar camomile components apigenin, apigenin-7-glucoside and apigenin-acetylglucoside with total flavonoid content 1-30 mg/ml, 0.1-3.0 wt% of a physiologically acceptable buffer to set the pH to 3.0-4.0 and opt. further physiologically acceptable auxiliaries, preservatives, perfumes, aromas and/or dyestuffs.
PURPOSE: An antibacterial formulation containing Vagococcus sp. VK24 with antibacterial function is provided to be used in an antibacterial agent and disinfectant. CONSTITUTION: A Vagococcus sp. strain VK24(KACC 91603P) is isolated from fish gastrointestinal tract and has bacteriosin productivity. An antibacterial formation contains the strain or bacteriosin prepared from the strain. The strain has excellent antibacterial activity in 0-1.76 wt% of salt. The bacteriosin suppresses the growth of Listonella anguillarum causing fish disease.
PROBLEM TO BE SOLVED: To obtain a viscosity-increasing agent useful as an infusing agent which is used for therapy of contract or glaucoma and treatment of ocular operation such as keratoplasty and the like an injection, a preparation for external use and an eye wash using for treating injury and the like on the surface of ocular tissues by formulating boric acid with hyaluronic acid. SOLUTION: The objective viscosity-increasing agent is obtained by dissolving (A) hyaluronic acid with a molecular weight of 100,000-3,000,000 and (B) boric acid in the form of free acid or salt into water in amounts of 0.001-0.5 wt.% and 0.1-5 wt.% calculated as the free acid, respectively. The viscosity-increasing agent is adjusted at pH 5-7.5. As long as the objective is achieved, other pharmaceutically active ingredients (e.g. antimicrobials, chelating agents, etc.), tonicity agents (e.g. sodium chloride and the like), buffers (e.g. sodium acetate and the like) and pH regulators can be added to the viscosity-increasing agent.  The viscosity of the aqueous solution of the component A tends to gradually decrease as days pass, but when the component B is added into the solution, the viscosity at the beginning when the solution is prepared is not only increased but the viscosity after days passed can also be maintained in remarkably high viscosity.
1,170,538. Stabilised veterinary compositions. IMPERIAL CHEMICAL INDUSTRIES Ltd. 17 June, 1968 [26 July, 1967], No. 34397/67. Heading A5B. N<SP>1</SP>-(1-methylallylthiocarbamoyl)-N-<SP>2</SP>-methylthio-carbamoylhydrazine (methallibure) particles are stabilized by coating substantially the whole of their surface with a water-repellant, non-toxic, orally acceptable fatty or waxy substance being a saturated or unsaturated aliphatic acid, a monodi or tri-glyceryl ester thereof, or an ester thereof with a fatty alcohol, or a fatty alcohol, or a paraffin hydrocarbon, of mpt. 30 to 120C and in which methallibure is essentially insoluble, or a mixture of such substances. The fatty or waxy substance may be a hydrogenated derivative of an oil of animal or vegetable origin e.g. hydrogenated castor, whale, ground nut or palm oil; stearic or palmitic acid; cetyl, stearyl or cetostearyl alcohols; spermacetic, Chinese wax, beeswax, paraffin or microcrystalline wax. The particles may contain from 0.5 to 10 parts by weight of fatty or waxy substance to one part by weight of methallibure. Veterinary compositions e.g. in the form of pre-mixes or medicated animal feedstuff comprises the particles together with a non-toxic diluent or carrier e.g. ground chalk, kaolin, talc or ground maize. The particles may be formed by adding powdered methallibure to the molten fatty or waxy substance, or mixture thereof, stirring and cooling the resulting mixture to form a friable mass which may be further broken up, ground and sieved to give a powder of particle size preferably below 350 microns. Alternatively powdered methallibure may be mixed with the fatty or waxy substance in powder form and the mixture is passed through a mill under conditions causing the fatty or waxy substance to melt and coat the particles of methallibure or a solution of the fatty or waxy substance in a volatile organic solvent may be sprayed on to the surface of particles of methallibure which becomes coated on evaporation of the solvent.
[GB1170538A]
NEW MATERIAL:The alanylproline derivative of formulaI(R is H or benzyl; x is residue of natural amoni acid; COOH and OH may be protected). EXAMPLE:Dibenzylphosphorylalanylprolylserine arginine salt. USE:A hypotensive agent. PROCESS:The dibenzylphosphoryl derivative of formulaI(R is benzyl) can be prepared e.g. by reacting the peptide derivative of formula II having protected carboxyl group with dibenzylphosphoryl chloride. The product can be converted to a phosphoryl derivative of formulaI(R is H) by hydrogenation using Pd-C as a catalyst. As an alternative method, the compound of formulaIcan be prepared by reacting dibenzylphosphorylalanylproline with an amino acid ester.
By one estimate, the demand for health care services related to pelvic floor disorders will increase at twice the rate of the population itself . So we need adequate understanding of the best surgical method for treating apical POP which is accepted worldwide and also must be cost effective with least perioperative complications. Abdominal sacropexy is considered now the gold standard operation for treatment of apical pelvic organ prolapse. In this technique, the mesh is ﬁxed to the anterior longitudinal ligament at the sacral promontory. It is used either with uterine preservation (sacrohysteropexy) or after hysterectomy (sacrocolpopexy) for treatment of vault prolapse .However , many intraoperative complication can occur including hemorrhage or transfusion or both occurred in 4.4% , intestinal injury or rectal injury in 1.6% (0.4% to 2.5%),and ureteral injury in 1.0% of cases. Postoperative complications include paralytic ileus in 3.6%.transient femoral nerve injury and vertebral osteomyelitis . Also, despite that sacropexy provide good apical support, but the high prevalence of cystocele and urinary tract symptoms in patients reaches up to 8% . Consequently, it is not surprising that the majority of failures following sacrocolpopexy occur in the anterior compartment. Lateral suspension with mesh was ﬁrst reported by Dubuisson in 1998 for the treatment of pelvic organ prolapse . The lateral suspension avoids both the risk of vascular injury and nerve damage of sacrocolpopexy with success rate up to 88% of cases.
After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
These patients will present for three treatments, each four weeks apart, with the abdominoplasty scheduled four weeks following the last laser treatment. These patients will receive laser treatment every four weeks for twelve weeks on the sites labelled Multiple Tx below (sites 1 and 2) on Days -90, -60, and -30 prior to abdominoplasty. At the final treatment (Day -30), two additional diodes will be placed on the sites labelled Single Tx below (sites 3 and 4). 4 diodes total will be used at this visit. Four weeks following this last treatment, the scheduled abdominoplasty will be performed and the pannus containing the treated tissue will be excised.
PURPOSE:To prepare the titled composition suitable for the prevention and remedy of periodontosis, esp. gingivitis, by using an organic solvent extract of a crude drug selected from the whole grass of melilotus herba, KOKA (flower of Carthamus tinctorius L.), KINGINKA (flower of Lonicera japonica Thunb.) and SHIKON (root of Lithospermum officinale L. var. erythrorhizon Maxim.), as an active component. CONSTITUTION:A composition for oral cavity application, containing the extract of melilotus, KOKA, KINGINKA, SHIKON, etc. with an organic solvent. The extract is effective for the prevention and remedy of periodontosis such as gingivitis, and is used as an ingredient to tooth paste, mouth wash, troche, ointment, massage cream for gingiva, etc. The solvent for extraction is e.g. a polar solvent such as lower alcohol, acetone, etc. a non-polar solvent such as benzen, etc. The extraction can be carried out by immersing the dried powder of the crude drug in hot solvent. The amount of the extraction in the whole composition is pref. 0.01-2%. The extract of horse chestnut (Aesculus hippocastanum) has similar effect, etc.
1. A pharmaceutical composition comprising particulate valdecoxib in an amount of about 1 mg to about 100 mg per dose and one or more pharmaceutically acceptable excipients, wherein a single dose, upon oral administration to a fasting subject, provides a time course of blood serum concentration of valdecoxib having at least one of (a) a time to reach a threshold concentration for therapeutic effect not greater than about 0.5 h after administration; (b) a time to reach maximum concentration (Tmax) not greater than about 3 h after administration; and (c) a maximum concentration (Cmax) not less than about 100 ng/ml. 2. The composition of Claim 1 wherein the threshold concentration for therapeutic effect is about 20 ng/ml. 3. The composition of Claim 2 wherein a single dose, upon oral administration to a fasting subject, provides a time course of blood serum concentration of valdecoxib having each of (a) a time to reach a concentration of 20 ng/ml not greater than about 0.5 h after administration; (b) a time to reach maximum concentration (Tmax) not greater than about 3 h after administration; and (c) a maximum concentration (Cmax) not less than about 100 ng/ml. 4. The composition of Claim 1 wherein the valdecoxib is in an amount of about 5 mg to about 40 mg per dose. 5. The composition of any of Claims 1 to 4 that is a tablet wherein the excipients comprise one or more diluents in an amount of about 5% to about 99%, one or more disintegrants in an amount of about 0.2% to about 30%, one or more binding agents in an amount of about 0.5% to about 25%, and one or more lubricants in an amount of about 0.1 % to about 10%, by weight of the composition. 6. The composition of Claim 5 wherein the binding agent is pregelatinized starch. 7. The composition of any of Claims 1 to 4 that is a tablet wherein the excipients comprise lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, pregelatinized starch and magnesium stearate. 8. The composition of Claim 1 further comprising one or more opioid or analgesic drugs. 9. The composition of any of Claims 1 to 8 wherein Dgo of the valdecoxib particles is less than about 75 mum. 10. The composition of any of Claims 1 to 8 wherein the valdecoxib particles have a weight average particle size of about 1 mum to about 10 mum. 11. The composition of any of Claims 1 to 8 wherein the valdecoxib particles have a weight average particle size of about 10 mum to about 1000 mum. 12. A method of preparing a composition of any of Claims 5 to 7 comprising a step of wet granulating valdecoxib together with one or more diluents and a binding agent, drying the resulting granules and compressing the resulting dry granulate to form a tablet. 13. A method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising orally administering to the subject a composition of any of Claims 1 to 12 once or twice a day. 14. A method of use of a composition of any of Claims 1 to 12 in manufacturing a medicament for treatment or prophylaxis of a cyclooxygenase-2 mediated disorder in a subject in need thereof.
Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
CABG is the most effective therapy for patients suffering from coronary artery disease, a condition which annually affects 126 million people worldwide. During this surgery, cardiopulmonary bypass (CPB) takes over the function of the heart and lungs. As a result of the emergence of minimally invasive cardiac surgery (MICS) (e.g. endoscopic-CABG), peripheral CPB with femoral arterial cannulation became the most commonly utilized strategy. However, the use of retrograde arterial perfusion is not without risk. It may result in the upper body and coronary arteries being perfused with deoxygenated blood. The hypoxemia will induce myocardial ischemia and this can harm the cardiac myocytes. A solution for this inconvenience is still lacking. Literature reports that establishing adequate ventilation support should help overcome this phenomenon. However, this approach has not yet been investigated in a clinical trial. In general, this phenomenon is not well recognized in the typical surgical setting, and limited research has been done.

The goal of the proposed pilot study is to determine which method can detect myocardial ischemia at the predefined timepoints during endo-CABG. Additionally, the investigators want to examine the influence of mechanical ventilation on the occurrence of myocardial ischemia in patients undergoing endo-CABG.
The gamma ethyl ester of L-glutamic acid (I) suitable for pharmaceutical use, is prepared by dissolution of L-glutamic acid (II) in ethanol, treatment with sodium methylate to form the monosodium salt with the gamma carboxylic group, treatment with ethyl iodide, and purification by suspension in aqueous ethanol. The above process gives a product suitable for oral administration. For intravenous administration the product is recrystallised from aqueous ethanol under sterile conditions. The solution is kept at 20-50 deg.C, pref. 35-40 deg. C, prior to addition of ethyl iodide. When recrystallisation of the produce is carried out, the aqueous ethanol solvent is pref. 40-80% ethanol, esp. 65% ethanol. This process gives a product that is free from the diethyl ester and the free acid (I).
Post-operative cognitive dysfunction (POCD) is an abrupt decline in neurocognitive function arising shortly after surgery and persisting for weeks to months, increasing the risk of dementia diagnosis. Advanced age, obesity, and comorbidities linked to high-fat diet (HFD) consumption such as diabetes and hypertension have been identified as risk factors for POCD, although underlying mechanisms remain unclear. We have previously shown that surgery alone, or 3-days of HFD can each evoke sufficient neuroinflammation to cause memory deficits in aged, but not young rats. The aim of the present study was to determine if HFD consumption before surgery would potentiate and prolong the subsequent neuroinflammatory response and memory deficits, and if so, to determine the extent to which these effects depend on activation of the innate immune receptor TLR4, which both insults are known to stimulate. Young-adult (3mo) & aged (24mo) male F344xBN F1 rats were fed standard chow or HFD for 3-days immediately before sham surgery or laparotomy. In aged rats, the combination of HFD and surgery caused persistent deficits in contextual memory and cued-fear memory, though it was determined that HFD alone was sufficient to cause the long-lasting cued-fear memory deficits. In young adult rats, HFD + surgery caused only cued-fear memory deficits. Elevated proinflammatory gene expression in the hippocampus of both young and aged rats that received HFD + surgery persisted for at least 3-weeks after surgery. In a separate experiment, rats were administered the TLR4-specific antagonist, LPS-RS, immediately before HFD onset, which ameliorated the HFD + surgery-associated neuroinflammation and memory deficits. Similarly, dietary DHA supplementation for 4 weeks prior to HFD onset blunted the neuroinflammatory response to surgery and prevented development of persistent memory deficits. These results suggest that HFD 1) increases risk of persistent POCD-associated memory impairments following surgery in male rats in 2) a TLR4-dependent manner, which 3) can be targeted by DHA supplementation to mitigate development of persistent POCD.
514,070. Grinding and crushing. LAWSON, R. W., and VERDIERS, E. E. April 26, 1938, No. 12491. [Class 59] [Also in Groups XXXVI, III, IV and VI] Natural silk is subjected to the action of aqueous acids or alkalies or other agents having a decomposing action but before the silk is completely decomposed or broken-up, the action is interrupted by treatment of the mass with a neutralizing agent whereby the mass is obtained as a slime of solid colloidal particles. The slime is subjected to an electrolytic treatment between an anode consisting of an alloy of copper, gold and silver, and an aluminium cathode and preferably at the same time it is subjected to the action of radio-active salts, or X-rays. The silk particles thus absorb metal particles. The slime is then dried and ground to an impalpable powder.
Inflammatory chemokines are a group of G-protein receptor ligands characterized by conserved cysteine residues, which can be divided into four main subfamilies: CC, CXC, XC, and CX3C. The C-X-C chemokine receptor (CXCR) 3 and its ligands, C-X-C chemokine ligands (CXCLs), are widely expressed in both the peripheral nervous system (PNS) and central nervous system (CNS). This comprehensive literature review aims to examine the functions and pathways of CXCR3 and its ligands in nervous system-related diseases. In summary, while the related pathways and the expression levels of CXCR3 and its ligands are varied among different cells in PNS and CNS, the MPAK pathway is the core via which CXCR3 exerts physiological functions. It is not only the core pathway of CXCR3 after activation but also participates in the expression of CXCR3 ligands in the nervous system. In addition, despite CXCR3 being a common inflammatory chemokine receptor, there is no consensus on its precise roles in various diseases. This uncertainty may be attributable to distinct inflammatory characteristics, that inflammation simultaneously possesses the dual properties of damage induction and repair facilitation.